Barchart on MSN1h
Gilead Sciences - Leader in HIV Medicines
Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...
MIT Technology Review4h
This annual shot might protect against HIV infections
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Managed Healthcare Executive14h
If Twice-Yearly Lenacapavir Could Be a HIV PrEP Game Changer, Would a Once-Yearly Version Be a HIV Epidemic Ender?
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
Why Gilead Sciences, Inc. (GILD) is the Best Pharma Stock to Buy According to Hedge Funds
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Researchers develop method to identify dormant cells that carry HIV
Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...
HIV Protection in One Injection? Gilead’s Lenacapavir Could Be a Game-Changer!
A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations., Hea ...
Applied Clinical Trials Online22h
Phase I Trial Supports Development of Once-Yearly Lenacapavir as Long-Acting HIV PrEP Option
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...